Among EGFR inhibitors, nimotuzumab (TheraCIM h-R3) and cetuximab (IMC-C225) have undergone an extensive evaluation in different tumour locations, showing activity when administered with ionising radiation (Bonner et al, 2004; Crombet et al, 2004; Ramos et al, 2006). Here, EGFR is linked to neoplasm.